Microfluidic models for adoptive cell-mediated cancer immunotherapies
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Current adoptive T cell therapies have shown promising results in clinical trials but need further development as an effective cancer treatment. Here, we discuss how 3D microfluidic tumour models mimicking the tumour microenvironment could help in testing T cell immunotherapies by assessing engineered T cells and identifying combinatorial therapy to improve therapeutic efficacy. We propose that 3D microfluidic systems can be used to screen different patient-specific treatments, thereby reducing the burden of in vivo testing and facilitating the rapid translation of successful T cell cancer immunotherapies to the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Clinical trials have yielded promising results for treating relapsed B cell acute lymphoblastic leukaemia (B-ALL) with T cells modified to express CD19 antibody as CAR infused into adult patients [11,12] or children [13,14].”
The present and future role of microfluidics in biomedical research
Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014) · Nature · doi:10.1038/nature13118 · Cited by 2,995 · cited 1×
“In addition to the enhanced capabilities of in vitro 3D models to mimic the physical and spatial characteristics of a tumour microenvironment, microfluidic platforms offer other advantages [45]:”
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · cited 1×
“Similarly, CD19-CAR T cells were infused into children and young adults with B-ALL or non-Hodgkin’s lymphoma [15].”
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“CRS has been observed, for example, in ACT targeting CD19 as a result of the great release of cytokines by CAR-expressing cells [21,22] but it can be effectively managed through the use of high-dose steroids or mAbs specific for inflammatory cytokines like IL-6 and tumour necrosis factor (TNF)-α.”
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 1×
“Clinical trials have yielded promising results for treating relapsed B cell acute lymphoblastic leukaemia (B-ALL) with T cells modified to express CD19 antibody as CAR infused into adult patients [11,12] or children [13,14].”
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · cited 2×
“Virus-based methods include retrovirus [7], lentivirus [8] and lymphotropic herpes virus vectors [9].”
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“Consequently, anti-CTLA-4 and anti-PD-L1 therapies have shown promise in overcoming the inhibitory signalling pathway [25].”
Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003) · Biotechnology and Bioengineering · doi:10.1002/bit.10655 · Cited by 934
Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function
Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., & Kamm, R. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210182109 · Cited by 872
Self-citationHuman 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation
Jeon, J. S., Bersini, S., Gilardi, M., Dubini, G., Charest, J. L., Moretti, M., & Kamm, R. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417115112 · Cited by 723
Self-citationA microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone
Bersini, S., Jeon, J. S., Dubini, G., Arrigoni, C., Chung, S., Charest, J. L., Moretti, M., & Kamm, R. D. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.050 · Cited by 534 · cited 1×
“where the 3D model to study organ-specific extravasation included breast cancer cells, osteo-differentiated bone-marrowderived mesenchymal stem cells and endothelial cells [50].”
Self-citationMicrofluidic system for formation of PC-3 prostate cancer co-culture spheroids
Hsiao, A. Y., Torisawa, Y.-S., Tung, Y.-C., Sud, S., Taichman, R. S., Pienta, K. J., & Takayama, S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.047 · Cited by 323 · cited 1×
“Similarly, a 3D bone microenvironment has been recreated to study prostate cancer cell metastasis [51] or the interactions between bone marrow cells and osteoblasts [52].”
Engineering cancer microenvironments for in vitro 3-D tumor models
Asghar, W., El Assal, R., Shafiee, H., Pitteri, S., Paulmurugan, R., & Demirci, U. (2015) · Materials Today · doi:10.1016/j.mattod.2015.05.002 · Cited by 316 · cited 1×
“To overcome some of these limitations, 3D in vitro models are being developed that offer the capability to investigate the role of the TME in a more physiologically realistic 3D condition compared with standard 2D in vitro assays [30].”
Mechanisms of tumor cell extravasation in an in vitro microvascular network platform
Chen, M. B., Whisler, J. A., Jeon, J. S., & Kamm, R. D. (2013) · Integrative Biology · doi:10.1039/c3ib40149a · Cited by 308
Self-citationA microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime
Zhang, Q., Liu, T., & Qin, J. (2012) · Lab on a Chip · doi:10.1039/c2lc00030j · Cited by 151
A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs
Kim, C., Kasuya, J., Jeon, J., Chung, S., & Kamm, R. D. (2015) · Lab on a Chip · doi:10.1039/c4lc00866a · Cited by 143
Self-citationNew dimensions in tumor immunology: what does 3D culture reveal?
Feder-Mengus, C., Ghosh, S., Reschner, A., Martin, I., & Spagnoli, G. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.001 · Cited by 139
A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation
Lee, H., Park, W., Ryu, H., & Jeon, N. L. (2014) · Biomicrofluidics · doi:10.1063/1.4894595 · Cited by 130
Bai, J., Adriani, G., Dang, T.-M., Tu, T.-Y., Leong Penny, H.-X., Wong, S.-C., Kamm, R. D., & Thiery, J.-P. (2015) · Oncotarget · doi:10.18632/oncotarget.4716 · Cited by 110
Self-citationMicrofluidic model of ductal carcinoma in situ with 3D, organotypic structure
Bischel, L. L., Beebe, D. J., & Sung, K. E. (2015) · BMC Cancer · doi:10.1186/s12885-015-1007-5 · Cited by 110 · cited 1×
“have cocultured mammary epithelial cells, ductal carcinoma in situ (DCIS) cells and human mammary fibroblasts (HMFs) in a 3D hydrogel to study DCIS cell progression [55].”
Drifka, C. R., Eliceiri, K. W., Weber, S. M., & Kao, W. J. (2013) · Lab on a Chip · doi:10.1039/c3lc50487e · Cited by 64 · cited 1×
“Moreover, supporting stroma cells in the TME have been considered to investigate the progression of pancreatic ductal adenocarcinoma [53] or ductal carcinoma in situ [54].”
A microfluidic model for organ-specific extravasation of circulating tumor cells
Riahi, R., Yang, Y. L., Kim, H., Jiang, L., Wong, P. K., & Zohar, Y. (2014) · Biomicrofluidics · doi:10.1063/1.4868301 · Cited by 60
Mattei, F., Schiavoni, G., De Ninno, A., Lucarini, V., Sestili, P., Sistigu, A., Fragale, A., Sanchez, M., Spada, M., Gerardino, A., et al. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.891677 · Cited by 57
Hsu, T.-H., Kao, Y.-L., Lin, W.-L., Xiao, J.-L., Kuo, P.-L., Wu, C.-W., Liao, W.-Y., & Lee, C.-H. (2012) · Integr. Biol. · doi:10.1039/c2ib00112h · Cited by 47
Cited by
Recent advances in microfluidic technologies for cell-to-cell interaction studies
Rothbauer, M., Zirath, H., & Ertl, P. (2018) · Lab on a Chip · doi:10.1039/c7lc00815e · Cited by 277
Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model
Ayuso, J. M., Truttschel, R., Gong, M. M., Humayun, M., Virumbrales-Munoz, M., Vitek, R., Felder, M., Gillies, S. D., Sondel, P., Wisinski, K. B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1553477 · Cited by 142
Characterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model
Lee, S. W. L., Adriani, G., Ceccarello, E., Pavesi, A., Tan, A. T., Bertoletti, A., Kamm, R. D., & Wong, S. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00416 · Cited by 109
“Prompted by our null observations in a 2D system, we moved toward a 3D microfluidic tumor model, which, among several other advantages, is a physiological improvement from the 2D in vitro system (43, 45).”
MethodSelf-citationDadgar, N., Gonzalez-Suarez, A. M., Fattahi, P., Hou, X., Weroha, J. S., Gaspar-Maia, A., Stybayeva, G., & Revzin, A. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-00201-6 · Cited by 99
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Metadata
- Authors
- Adriani, G., Pavesi, A., Tan, A. T., Bertoletti, A., Thiery, J. P., & Kamm, R. D.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 21
- Issue
- 9
- Pages
- 1472-1478
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2374762237
- Cited by
- 66
- References
- 25
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.